[6 June, 2016]
The Access to Medicine Foundation report explores the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of research & development (R&D) models in incentivizing these contributions. For the past 10 years, the Access to Medicine Foundation has tracked the progress of pharmaceutical engagement in R&D for neglected diseases, they found that models like Product Development Partnerships (PDPs) have been highly successful in creating incentives for pharmaceutical companies to participate in access-friendly R&D.
Ways that PDPs incentivize collaboration:
- Mitigate risk
- Pooled resources in priority disease areas
- Ensuring future access
Incorporating the lessons learned from such models could lead to the creation of a successful system that influences others to drive similar innovations in R&D for neglected populations.
Download the report: “Ensuring sustained incentives for pharmaceutical companies to develop medicine for the poor”